1,721,515 research outputs found
Clinical Challenge. Comments to Case study no.23. Further imaging by retrograde cystography and/or intravaginal ultrasound may help diagnosis
No full textEditorial comment on: Tension-Free Midurethral slings in the treatment of stress urinary incontinence: a systematic review and meta-analysis of randomized trials of effectiveness
No full text
ESU Course 6: Prolapse management. Managing complications
No full textManagement of complications after POP repai
Editorial comment on: Cizolirtine Citrate is safe and effective for treating Urinary Incontinence secondary to overactive bladder: a Phase 2 proof-of-concept study
No full textOveractive bladder (OAB) has high prevalence in
women and men and has a significant negative impact
on quality of life as well as growing costs for treatment
[1,2]. Antimuscarinics are used as first-line drug therapy
for OAB. Currently, a considerable number of antimuscarinic
drugs are on the market. Moreover, dose flexibility
and different drug formulations improve the efficacy of
antimuscarinic agents [3]. Patient compliance and treatment
persistence, however, are still insufficient in clinical
practice [4]. Recent neuropharmacologic developments in
the understanding of the micturition reflex have led to
new alternative therapeutic modalities for OAB.
The present paper by Za ́ t’ura and coworkers reports the
safety and effectiveness of a new agent in the treatment of
OABwith urinary incontinence [5]. The study was designed
as a multicenter, randomized, double-blind phase 2
protocol. The primary objective was to prove the clinical
efficacy of cizolirtine citrate, an inhibitor of substance P and
calcitonine gene-related peptide release at the spinal-cord
level, comparedwith placebo. In the previous pilot study of
79 symptomatic patients with urinary incontinence secondary
to OAB, the authors showed evidence of therapeutic
efficacy and good tolerability of cizolirtine citrate using two
dosages: 200 mg twice a day (bid) and 400 mg bid [6]. The
present trial of 135 patients confirms the results of the pilot
study, showing a significant reduction of the total number
of voidings per 24 h. Moreover, the authors conclude that
cizolirtine citrate (400 mg bid) may be suitable as a
complementary or alternative agent to antimuscarinics in
the treatment of OAB. Adverse events caused by cizolirtine
citrate were similar to those caused by anticholinergics,
with predominantly gastrointestinal and neurologic symptoms.
Further research with more detailed objective assessment
of OAB symptoms as well as patient group
definitions are needed to prove the efficacy and safety
of cizolirtine citrate. Phase 3 studies related to the
comparability of this promising new agent and the
antimuscarincs are necessary
- …
